BRIEF published on 09/18/2024 at 10:13, 16 hours 50 minutes ago Mirova crosses the threshold of 5% of voting rights in MEDINCELL Voting Rights Actions Threshold Crossing Medincell Mirova
BRIEF published on 09/18/2024 at 10:13, 16 hours 50 minutes ago Mirova franchit le seuil des 5% des droits de vote de MEDINCELL Droits De Vote Franchissement De Seuil Actions Medincell Mirova
PRESS RELEASE published on 09/18/2024 at 10:08, 16 hours 55 minutes ago Franchissement de seuil Déclaration de franchissement de seuil par Mirova pour le compte de fonds qu'elle gère concernant MEDINCELL sur Euronext Paris Euronext Paris Franchissement De Seuil Gestion Medincell Mirova
BRIEF published on 09/11/2024 at 07:35, 7 days 19 hours ago Medincell établit un nouveau contrat de liquidité avec Rothschild Martin Maurel Euronext Paris Contrat De Liquidité Rothschild Martin Maurel Actions Ordinaires Medincell
BRIEF published on 09/11/2024 at 07:35, 7 days 19 hours ago Medincell establishes a new liquidity contract with Rothschild Martin Maurel Common Shares Euronext Paris Liquidity Contract Rothschild Martin Maurel Medincell
PRESS RELEASE published on 09/11/2024 at 07:30, 7 days 19 hours ago Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité Medincell confie son Contrat de liquidité à ROTHSCHILD MARTIN MAUREL pour animer ses actions sur Euronext Paris, conformément à la réglementation en vigueur Euronext Paris Contrat De Liquidité Rothschild Martin Maurel Réglementation Medincell
PRESS RELEASE published on 09/11/2024 at 07:30, 7 days 19 hours ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Medincell appoints ROTHSCHILD MARTIN MAUREL for liquidity contract management on Euronext Paris, complying with AMF Decision 2021-01 Euronext Paris Liquidity Contract Rothschild Martin Maurel AMF Decision Medincell
BRIEF published on 09/05/2024 at 07:35, 13 days 19 hours ago Medincell: Promising advances for injectable Olanzapine Schizophrenia Phase 3 Medincell Olanzapine Teva Pharmaceuticals
BRIEF published on 09/05/2024 at 07:35, 13 days 19 hours ago Medincell : avancées prometteuses pour l'Olanzapine injectable Schizophrénie Phase 3 Medincell Olanzapine Teva Pharmaceuticals
PRESS RELEASE published on 09/05/2024 at 07:30, 13 days 19 hours ago Informations privilégiées / Autres communiqués Teva, partenaire de Medincell, annonce des avancées importantes dans l'essai clinique pivot de phase 3 de l'Olanzapine injectable à durée d’action prolongée, avec un taux élevé d'injections réalisées et des résultats positifs attendus Schizophrénie Essai Clinique Medincell Olanzapine Teva
Published on 09/18/2024 at 23:10, 3 hours 54 minutes ago Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Published on 09/18/2024 at 23:00, 4 hours 4 minutes ago Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Published on 09/18/2024 at 21:15, 5 hours 49 minutes ago New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Published on 09/18/2024 at 21:00, 6 hours 4 minutes ago Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Published on 09/18/2024 at 16:30, 10 hours 34 minutes ago Manimal Tales Launches New Nursery Rhyme Based Detective Series: Your Child Solves Nursery Crimes in our Newest Personalized Book!
Published on 09/18/2024 at 19:11, 7 hours 53 minutes ago EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Published on 09/18/2024 at 18:45, 8 hours 19 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/18/2024 at 18:31, 8 hours 32 minutes ago EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Published on 09/18/2024 at 18:13, 8 hours 51 minutes ago BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Published on 09/18/2024 at 17:21, 9 hours 42 minutes ago EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Published on 09/18/2024 at 18:45, 8 hours 18 minutes ago Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Published on 09/18/2024 at 18:45, 8 hours 18 minutes ago Capital increase following the allocation of free shares to EuropaCorp employees
Published on 09/18/2024 at 17:40, 9 hours 24 minutes ago Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.